Background/Aims: Osteoporosis is a bone metabolic disease characterized by a systemic impairment of bone mass, which results in increased propensity of fragility fractures. A reduction in the differentiation of MSCs into osteoblasts contributes to the impaired bone formation observed in osteoporosis. Mesenchymal stem cells (MSCs) are induced to differentiate into preosteoblasts, which are regulated by the signaling cascades initiated by the various signals, including miRNAs. miR-16-2* is a newly discovered miRNA that participates in diagnosis and prognosis of hepatocellular carcinoma, cervical cancer and chronic lymphocytic leukemia. However, the effect of miR-16-2* on the regulation of osteoblast differentiation and the mechanism responsible are still unclear. Here we discuss the contribution of miR-16-2* to osteoporosis, osteoblast differentiation and mineralization. Methods: The expression pattern of miR-16-2* during osteogenesis or in osteoporosis bone samples was validated by quantitative real-time PCR (qRT-PCR). The human bone marrow mesenchymal stem cells (hBMSCs) were induced to differentiate into osteoblasts by osteogenic induced medium containing dexamethasone, ascorbate-2-phosphat, beta-glycerophosphate and vitamin-D3. The target genes of miR-16-2* were predicted by TargetScan and PicTar. The mRNA and protein levels of osteogenic key markers were detected using qRT-PCR or western blot respectively. The WNT signal activity was analyzed by TOP/FOP reporter assay. Results: The expression of miR-16-2* in patient bone tissue with osteoporosis was negatively correlated with bone formation related genes. During osteoblast differentiation process, the expression of miR-16-2* was significantly decreased. Upregulation of miR-16-2* in hBMSCs impaired the osteogenic differentiation while the downregulation of miR-16-2* increased this process. Upregulation the expression of miR-16-2* could also block the WNT signal pathway by directly target
Introduction
In countries with large aging popula tions, such as China [1] , osteoporosis is a common and systemic bone metabolic disease characterized by loss of bone mass and increase in fragility fractures. Osteogenesis is a complex multi-step process involving the differentiation of mesenchymal stem cells (MSCs) into osteoblast progenitor cells, preosteoblasts, osteoblasts and osteocytes. By secreting bone matrix protein alkaline phos phatase (ALP) and that induce bone matrix mineralization, osteoblasts have been widely accepted as the major cells that contribute to osteogenesis and bone formation [2, 3] . A reduction in the differentiation of MSCs into osteoblasts contributes to the impaired bone formation observed in osteoporosis. Therefore, understand ing the underlying mechanism involved in the osteoblast differentiation from MSCs and activation pro cesses is in urgent need for the treatment of osteogenesis imbalanced diseases. Recent research has found MSCs are induced to differentiate into preosteoblasts, which are tightly regulated by several factors, including microRNAs (miRNAs).
miRNAs are a class of evolutionarily conserved, small noncoding RNA molecules (18-25 nucleotides), which control gene expression at a posttranscriptional level through binding to the seed sequences of the 3'-untranslated region (UTR) of target messenger RNAs (mRNAs) and mediating the degradation of mRNA or translation inhibition [4, 5] . miRNAs have been shown to play critical roles in a wide variety of biological processes, including proliferation, lineage commitment, differentiation, cell cycle, invasion and apoptosis [6] [7] [8] [9] [10] . Recently, increasing evidences have indicated that bone development and homeostasis is regulated by miRNAs [11] [12] [13] [14] .
miR-15/16 family [15] [16] [17] [18] encompasses the miR-15a/16-1 cluster (on chromosome 13q14,) the miR-15b/16-2 cluster (on chromosome 3q25), and the miR-195/497 cluster (on chromosome 17p13). miR-16-2 on chromosome 3 rather than of miR-16-1 on chromosome 13. Whereas miR-15a is highly similar to miR-15b, miR-16-1 is identical to miR-16-2. Thus, it could be speculated that both clusters control a similar set of target genes and may have overlapping functions. However, the biological role of miR-15b/16-2 is still controversial. The central role of the miR-15a/16-1 cluster in oncogenesis has been extensively demonstrated. The circulatory miR-16-2 level has been established as critical factor for diagnosing hepatocellular carcinoma, cervical cancer and chronic lymphocytic leukemia [19] [20] [21] . However, the central role of this miRNA in osteogenesis is still far from being elucidated.
Recently, we found that mature miR-16-2* (also name as miR-16-2-3p) levels are abnormally expressed in bone samples of patients with osteoporosis, which suggest an important role of miR-16-2* in the regulation of MSC osteogenic differentiation. The aim of this study is to characterize the expression of miR-16-2* in osteoporo sis and investigate its effects on osteoblast dif ferentiation, as well as the potential molecular mechanisms.
Materials and Methods
Clinical bone specimen preparation and RNA extraction Forty-six clinical bone specimens were collected from the Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine. The clinical bone sample was originally from patients at the age between 55 and 70 years old. Exclusive criteria: individuals with diabetes, malignancy or other severe diseases in the previous 5 years; inclusive criteria: patients who with low-energy fractures [22, 23] . All of the clinical procedures were approved by the IRB of Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine.
Osteogenic differentiation
Osteogenic induction was performed as described previously [23] . Cells were grown in 6-well plates, when reached 70-80% confluence, cells were transfected. Twenty-four hours after transfection, osteogenic differentiation was started on hBMSCs by replacing the growth medium with an osteogenic differentiation medium consisting of Dulbecco's modified Eagle's medium (DMEM), 10% FCS (SigmaAldrich, Munich, Germany), 4 mM Lglutamine, 10 nM dexamethasone (Sigma-Aldrich), 10 nM calcitriol (1α,25-dihydroxyvitamin D3; Sigma), 150 mM ascorbate-2-phosphat, 10 mM beta-glycerophosphate (Sigma-Aldrich). Medium was refreshed every two days. Measurement of alkaline phosphatase (ALP) expression and ALPase activity served as early marker for osteogenesis and were detected by ALP staining and quantitative ALP activity measurement. Calcium deposits as late marker for osteogenesis were confirmed by Alizarin Red S staining.
ALP staining and ALPase activity measurement ALP staining was monitored using an ALP staining kit (Beyotime® Institute of Biotechnology, Shanghai, China) according to the manufacturerʹs protocol. Cellular ALP activity was measured with an ALP activity kit (GENMED, Shanghai, China). Briefly, the cells were washed twice with PBS, and incubated in an ALP stain ing solution (Sigma-Aldrich) at 37°C for 20 min with gentle shaking in the dark. ALPase activity was measured with a spectrophoto metric method by a p-Nitrophenyl Phosphate Liquid Substrate System (Sigma-Aldrich). The absorbance at 405 nm of each well was assayed with a microplate reader (BD Biosciences, Franklin Lakes, NJ, USA) according to the man ufacturer's instruction. The ALPase activity was normalized to the protein concentration.
Alizarin red staining (ARS)
Cells were washed with PBS, fixed in 4% paraformaldehyde (Sigma-Aldrich) for 10 min at room temperature. After removing the fixative, cells were rinsed with double-distilled H 2 O and stained with 40 mM alizarin red (Sigma), with pH 4.2 for 30 min with gentle agitation at room temperature. Cells were then rinsed with double-distilled H 2 O to remove the excess dye and subsequently photographed. For quantification, to eluted the bound dye, stained cells were incubated in 800 μL of acetic acid for 30 min at room temperature as previously described [24] , and then measured using a microplate reader (BD Biosciences, Franklin Lakes, NJ, USA) at 405 nm.
Quantitative real-time PCR (qRT-PCR) analysis
Total RNA was extracted using Trizol reagent (Gibco, Carlsbad, CA, USA) according to the manufacturer's instructions, and was reverse transcribed into cDNA using the PrimeScript RT Reagent Kit (#DRR037A; TaKaRa). The complementary DNA was synthesized from 1 μg total RNA using the PrimeScript RT Reagent Kit (#DRR037A; TaKaRa). The amplification of marker genes was performed by quantitative real-time PCR (qRT-PCR). qRT-PCR was performed with an SYBR Green qPCR kit (Toyobo, Osaka, Japan) on an ABI PRISM 7900 Real-time PCR System (Applied Biosystems, Carlsbad, CA, USA). The primers used in this study are shown in Table 1 . The extraction, reverse transcription, and qPCR of the miRNA were realized by use of the corresponding kit from GeneCopoeia. The primers for miR-16-2* and the endogenous control U6 were purchased from GeneCopoeia. 
Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry miRNA and siRNA transfection Transfection was performed using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. The miRNA mimic, inhibitor, and their negative controls for miR-16-2*; small interfering RNA (siRNA) duplex oligos targeting WNT5A mRNA and miR-16-2* mRNA; and negative duplex oligos (siRNA negative controls) were purchased from Genepharma (Shanghai, China). Cells were cultured overnight in six-well or twenty-four plates until they reached 50% confluence were transfected with miRNA mimics/inhibitors/siRNA or negative control at a final concentration of 100 nM according to the manufacturer's instructions of Lipofectamine 2000.
TOP/FOP reporter assay
The activity of the Wnt signaling pathway was detected by a Wnt signal reporter assay using the TOPglow/FOPglow TCF reporter kit (Millipore). TOPglow (cat. # 21-204) is transfection grade T cell factor (TCF) reporter plasmid which containing four copies of the TCF binding site (WT) upstream of E1B TATA box and luciferase open reading frame. FOPglow (cat. # 21-205) is transfection grade T cell factor (TCF) reporter plasmid containing three copies of the TCF binding site (mutated) upstream of E1B TATA box and luciferase open reading frame. This plasmid serves as a negative control to TOPglow. Cells were seeded in 6-well plates and transfected with TOPglow and FOPglow according to the manufacturer's instructions. All transfections were done in triplicate and repeated at least 3 times.
Western blotting analysis
Cells were lysed in RIPA buffer (Beyotime, Shanghai, China) supplemented with roteinase and phosphatase inhibitors (Roche). Protein was manually scraped from culture plates and then sonicated and quantified using the BCA Protein Assay Kit (Beyotime). Protein fractions were separated using 10% SDS/ PAGE and transferred to a PVDF membrane (UltraCruz). Then, the membranes were blocked in 5% BSA for 1 hour, incubated with specific antibodies at 4 °C overnight, and then with secondary antibodies for 1 hour. The blots were detected with ECL reagent (Millipore).
Luciferase reporter assay
TargetScan (http://www.targetscan.org) and PicTar (http://pictar.mdc-berlin.de/) software were used in this study to identify miR-16-2* potential tar gets. An 80-to 100-bp synthetic fragment of the 3ʹUTR of SMAD5, BMP4, BMPR1A, WNT5A, FZD3, FZD5 containing the putative miR-16-2* recognition sequence and corresponding mutated 3ʹUTR were subcloned into the psiCHECK-2 vector (Promega, Southampton, UK) downstream of the renilla luciferase reporter gene. HEK293T cells were seeded in 24-well plates at a density of 1 × 10 5 cells per well. Overnight HEK293T cells were co-transfected with the luciferase reporter vector and miR-16-2* mimic, miRNA mimic negative control (miR-NC), miR-16-2* inhibitor (miR-16-2*I) or miRNA inhibitor negative control (miR-NCI). Transfection assay was conducted using lipofectamine 3000 (Invitrogen). Firefly and Renilla luciferase activities were detected 48 h after transfection using the dual-luciferase reporter assay system (Promega Corporation, Madison, WI, USA). The Renilla val ues were normalized to firefly luciferase. Each experiment was repeated in triplicate.
Statistical analysis
Data are presented as the mean ± SD from at least three time independent experiments. Significant differences between groups or multiple groups were analyzed using Studentʹs t-tests or one-way ANOVA respectively. Spearman rank order was used to analyze the correlations between variables. Differences were considered statistically significant at *P<0.05, **P<0.01 and ***P<0.001.
Results

miR-16-2* is negative correlated with bone formation and downregulated during osteogenic differentiation
To determine whether miR-16-2* is related to bone formation, the expression levels of miR-16-2* in clinical bone specimen were analyzed using qRT-PCR. Results showed that the expression of miR-16-2* in clinical bone specimen was negative correlated with the Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry expression of key genes of bone formation (Fig. 1A ), indicating that miR-16-2* was involved in the progression of bone formation. We then detected the expression levels of miR-16-2* during osteogenic differentiation of hBMSCs. A num ber of key osteoblast markers, including RUNX2, OSX, OCN, ALP, OPN and COL1A1, were used as phenotypic markers of osteogenic differentiation. The expressions of all the mark ers above and the activity of ALPase were obvious ly increased in the osteogenic medium treated cells, indicat ing that osteogenic differentiation had been successfully induced ( Fig. 1B and 1C) . Results of miRNA specific qRT-PCR showed that miR-16-2* expression levels decrease significantly in along with the time course during osteoblast differentiation (Fig. 1D) . These results demonstrated that miR-16-2* may have a role in the progression of osteogenic differentiation.
Forced expression of miR-16-2* in BMSCs suppressed osteoblast differentiation
In order to assess the physiological role of miR-16-2* on osteogenic differentiation and bone formation, BMSCs were transfected with either miR-16-2* mimic or control and cultured under osteogenic induced medium. MiRNA specific qRT-PCR analysis confirmed that transfection of BMSCs with control does not affect endogenous miR-16-2* level, while miR-16-2* mimic transfection markedly increased miR-16-2* level ( Fig. 2A) and resulted in significantly reduced levels of key transcription factors for osteogenic differentiation, The dynamic expression of miR-16-2* during osteoblast differentiation of hBMSCs. All data were presented as the mean ± SD from three independent experiments, and U6 was used as an internal normalization control. (Fig. 2B) . Similar changes were also observed in western blotting analysis of these genes (Fig. 2C ). miR-16-2* mimic transfection weaken ALP staining, decreased ALPase activity in differentiated cells and markedly suppressed calcification of induced cells which detected by ARS staining (Fig. 2D-F) . Collectively, these results demonstrated that forced expression of miR-16-2* can suppress the progression of osteoblast differentiation. GAPDH was used as an internal control in RT-PCR and western blot analysis of genes. U6 was used as an internal normalization control of miRNA. Quantitative data were presented as the mean ± SD (n = 3), *P<0.05; **P<0.01; ***P<0.001 compared with their negative control. All the staining and western blot images were confirmed by at least three repeated trails. Scale bar is 100 mm.
Figure 2
Cell
Downregulation of miR-16-2* enhances the osteoblast differentiation
In order to further explore the effects of miR-16-2* for osteoblast differentiation, we suppressed the expression of miR-16-2* in hBMSCs with inhibitors (Fig. 3A) . Results showed that downregulation of miR-16-2* markedly increased the mRNA expression levels of key transcription factors for osteoblast differentiation, RUNX2, OSX and ALP, as well as known osteoblast differentiation and lineage commitment marker genes, OCN, OPN and COL1A1 (Fig. 3B) . Similar changes were also observed at protein level of these genes through western GAPDH was used as an internal control in RT-PCR and western blot analysis of genes. U6 was used as an internal normalization control of miRNA. Quantitative data were presented as the mean ± SD (n = 3), *P<0.05; **P<0.01; ***P<0.001 compared with their negative control. All the staining and western blot images were confirmed by at least three repeated trails. Scale bar is 100 mm. (Fig. 3C) . The ALP staining and activity of ALPase in the miR-16-2* inhibitor (miR-16-2*I) transfected cells were significantly increased, compared with the miRNA inhibitor negative control (miR-NCI) transfect ed cells (Fig. 3D, E) . ARS staining to indicate calcification was also enhanced markedly in the miR-16-2*I transfected cells (Fig. 3F) . These data further confirmed that downregulation of miR-16-2* can enhance the osteoblast differentiation of BMSCs.
Figure 3
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WNT5A is a direct target gene of miR-16-2*
To identify targets mediating the inhibitory effect of miR-16-2* on osteoblast differentiation, we predicted the potential targets in silico using various databases. Take complementarity of the miRNA seed sequence into account, TargetScan and PicTar showed that SMAD5, BMP4, BMPR1A, WNT5A, FZD3, FZD5, have binding site of miR-16-2* seed sequence in their 3'UTR ( Table 2) . To further confirm the interaction between miR-16-2* seed sequence and the 3'UTR of its potential target genes, luciferase reporter assay was performed ( Fig. 4A and 4B) . Results showed that miR-16-2* directly bound on the 3'UTR of WNT5A mRNA, while not targeted the 3'UTR of WNT5A mRNA with mutant seed region or other genes 3'UTR as mentioned above (Fig. 4C) . We then analyzed the regulation effect of miR-16-2* on the expression of its potential target WNT5A. Consistent with the luciferase reporter assays, qRT-PCR and western blotting analyses also showed that miR-16-2* mimic decreased WNT5A expression at protein level most significantly (Fig. 4D) . These data suggested that miR-16-2* can bind the 3'UTR of WNT5A mRNA and regulate its expression at the posttranscriptional level in hBMSCs.
Downregulation of WNT5A simulated the inhibitory effect of miR-16-2* on osteoblast differentiation
To further confirm the interaction between miR-16-2* and WNT5A, we suppressed the endogenous expression level of WNT5A by siRNA. qRT-PCR and western blotting confirmed that WNT5A was significantly suppressed by siWNT5A at both mRNA and protein levels (Fig.  5A, B) . Then we analyzed the effect of WNT5A downregulation on osteoblast differentiation of hBMSCs. qRT-PCR results showed that transfection of siWNT5A sharply decreased the mRNA expression levels of RUNX2, OSX and ALP, as well as known osteoblast differentiation and lineage commitment marker genes, OCN, OPN and COL1A1, compared with the transfection of siRNA negative control (siNC) (Fig. 5C ). Similar changes were also observed at protein levels of these genes through western blotting analysis (Fig. 5D) . The ALP staining and the activity of ALP were decreased significantly in the siWNT5A-transfected cells, compared with the siNC transfect ed cells (Fig. 5E, F) . Calcium deposition in the siWNT5A transfected cells was sharply less than the siNC transfect ed cells, indicated by ARS staining (Fig. 5G) . These results revealed that repression of target gene WNT5A can simulate the effect of miR-16-2* overexpression on osteoblast differentiation of hBMSCs, which confirmed that the interaction between miR-16-2* and WNT5A plays a pivotal role of in regulation of osteoblast differentiation.
miR-16-2* interferes with WNT signaling to regulate osteoblast differentiation
WNT5A is an important member of the WNT pathway. To further explore the interaction between miR-16-2* and WNT signaling, we performed a dosage experiment to block WNT signaling by DKK1. WNT signaling inhibitor, DKK1 of different concentrations was added into the osteoblast induction medium during osteogenic differentiation of hBMSCs. Results (D) Western blotting and qRT-PCR analyzed the effect of miR-16-2* on WNT5A expression. GAPDH was used as an internal control in RT-PCR and western blot analysis of genes. U6 was used as an internal normalization control of miRNA. Quantitative data were presented as the mean ± SD (n = 3), *P<0.05; **P<0.01; ***P<0.001 compared with their negative control. All the staining and western blot images were confirmed by at least three repeated trails. Scale bar is 100 mm.
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showed that DKK1 significantly suppressed the osteogenic differentiation of hBMSCs in a concentration-dependent manner, which was indicated by the reduction of ALP staining, delay mineral deposition, and decrease ALP activity (Fig. 6A, B) . Furthermore, the promotion of hBMSCs osteoblast differentiation by miR-16-2* inhibitor was almost abrogates by 1 nM DKK1, as indicated by decreased ALP staining and ALP activity, suppressed the expression of key transcription factors and marker genes of osteoblast differentiation, and blocked mineral deposition ( Fig. 6C-E) . Then, the activity of the Wnt signaling pathway was detected by TOP/ FOP reporter assay. Results showed that the overexpression of miR-16-2* or interference with endogenous WNT5A decreased the activity of Wnt signaling pathway, while the inhibition of miR-16-2* enhanced it (Fig. 6F) . qRT-PCR further confirmed that the expression levels of CTNNB1 and LRP5/6 were significantly reduced in the overexpression of miR-16-2* (E and F) ALP staining and ALPase activity assay were performed to indicate ALP expression and ALPase activity on day 6 of induced cells. (G) ARS staining was performed to indicate mineral deposition on day 12 of induced cells. GAPDH was used as an internal control in qRT-PCR and western blot analysis of genes. U6 was used as an internal normalization control of miRNA. Quantitative data were presented as the mean ± SD (n = 3), *P<0.05; **P<0.01; ***P<0.001 compared with their negative control. All the staining and western blot images were confirmed by at least three repeated trails. Scale bar is 100 mm.
5
Figure 5
Cell GAPDH was used as an internal control in RT-PCR and western blot analysis of genes. U6 was used as an internal normalization control of miRNA. Quantitative data were presented as the mean ± SD (n = 3), *P<0.05; **P<0.01; ***P<0.001 compared with their negative control. All the staining and western blot images were confirmed by at least three repeated trails. Scale bar is 100 mm.
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or interference with endogenous WNT5A, and were upregulated in the suppression of miR-16-2* (Fig. 6G-I ). Summarily, these data further suggest that miR-16-2* interferes with WNT signaling to regulate osteoblast differentiation of hBMSCs.
Discussion
Despite miR-16-2* has been established as critical factor for diagnosing cervical cancer, the central role of this miRNA in osteogenesis is still far from being elucidated. In this study, we show that mature miR-16-2* levels are abnormally increased in bone of patients with osteoporosis. Forced expression of miRNA-16-2* in mesenchymal stem cells suppressed osteogenesis. miR-16-2* interferes with WNT signaling to regulate osteoblast differentiation though directly suppressing WNT5A. These results are the first to suggest an important role of miR-16-2* in the regulation of MSC osteogenic differentiation, and abnormal expression of miR-16-2* may be responsible for the process of osteogenesis.
Osteoporosis characterized by low bone mineral density and low trau ma fractures, is a common and progressive skeletal disorder-related disease in aging people worldwide. By secreting alkaline phos phatase and bone matrix proteins that induce bone matrix mineralization, osteoblasts act as the major cells that contribute to bone formation. Reduce the ability of mesenchymal stem cells (MSCs) differentiate into osteoblast (named as osteogenesis, osteogenic or osteoblast differentiation) would lead to the decrease of bone mineral density and disrup tion of bone microarchitecture [25] , then the imbalance of bone remodeling, and finally result in osteoporosis. Therefore, understand ing the underlying mechanism involved in the osteoblast differentiation and activation pro cesses is in urgent need for the treatment of bone formation imbalanced diseases.
Osteogenesis is a complex multi-step process involving the differentiation of MSCs into osteoblast progenitor cells, preosteoblasts, osteoblasts and osteocytes, and the crosstalk between multiple cell types for the formation and remodeling of bone. Differentiation of MSCs into mature osteoblastic cells, regulation of osteoblast functions and the formation of bone by osteoblast cells and their primary functional activities, involve highly regulated processes mediated by a series of multiple signals, including BMPs, TGFβ, PI3K, WNT, NOTCH, as well as other growth factors and hormones [26] [27] [28] [29] . BMPs are essential for organogenesis in early and late development. Deletion of BMP ligands [30] or BMP receptors [31] from the limb bud mesenchyme impairs chondrogenic or osteogenic differentiation and induces skeletal patterning defects. A second major molecular pathway involved in osteoblastogenesis is WNT signaling. WNTs are historically categorized by whether they signal in a canonical or non-canonical manner. WNT signaling pathway regulates bone formation through β-catenindependent canonical and -independent non-canonical signaling pathways. However, complex cross talk between various molecular pathways [32] , make it difficult to coordinated regulation osteogenesis differentiation through single gene.
The canonical WNT signaling pathway plays an important role in bone differentiation and bone formation [33] [34] [35] [36] . The canonical WNT3A and the non-canonical WNT5A have the effect of promoting bone formation in collaboration with each other. DKK1, an important inhibitor of canonical WNT signaling pathway, also significantly suppressed the osteogenic differentiation of hBMSCs in a concentration-dependent manner. The WNT5A of the noncanonical WNT pathway is also reported to play an important role in bone formation and osteoblast differentiation. WNT5A+/-mice had a reduction in bone mass with a reduced number of osteoblasts, whereas an increased number of adipocytes were seen in the bone marrow. Wnt5a has been shown to induce osteoblastogenesis through the attenuation of PPARG-induced adipogenesis in bone marrow mesenchymal stem cells [37] . WNT5A is critical for the pro-osteogenic effects of iron chelation using deferoxamine [38] . We found that inhibiting WNT5A significantly impaired the ability of MSC to differentiate into osteoblasts. Other studies have found that the canonical WNT3A and the non-canonical WNT5A have the effect of promoting bone formation in collaboration with each other. If Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry rWNT3A was supplemented during a time window following rWNT5A treatment, osteogenic differentiation was enhanced both in murine and human ESCs [39] . Sphingosine-1-phosphate (S1P) -enhanced Wnt5a promotes low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6) expression, resulting in the trigger of osteogenic differentiation of C3H10T1/2 cells [40] . The lack of Wnt5a in osteoblast-lineage cells impaired Wnt/β-catenin signaling due to the reduced expression of LRP5 and LRP6 [41] . These results confirmed a pivotal role of WNT signaling in the regulation of osteoblast differentiation. We demonstrated that downregulate Wnt5a decreased the expression of CTNNB1, LRP5 and LRP6 during osteoblast differentiation of bMSCs. Recently, miRNAs have been found to be important regulators of osteogenic signaling pathways in multiple aspects and multiple signaling pathways. MiRNAs are short non-coding RNA molecules of 17-25 nucleotides that control gene expression at the post-transcriptional level and have been shown to play critical roles in a wide variety of biological processes, including proliferation, reprogramming, differentiation, cell cycle, invasion and apoptosis [6, 7, 9, [42] [43] [44] . Each miRNA regulates numerous mRNAs and involve multiple signaling pathways. Increasing evidences have indicated that miRNAs play multiple functions in skeletal development, bone formation and remodeling, and osteoblast differentiation, through regulation of the osteoblastic phenotype related essential signaling pathways [23, [45] [46] [47] [48] . For example, under osteogenic differentiation, multiple miRNAs such as miR-17-5p and miR-106a that attenuate RUNX2 and SMAD signal is by suppressing BMP2 [49] . Early expression of miR-195-5p inhibits differentiation and mineralization via altering the gene regulatory network of osteoblast differentiation and impairing the induction of BMP responsive genes. Through targeting BMP-7 and inhibiting BMP-7/PI3K-survivin signaling, miR-542-3p suppresses osteoblast cell proliferation and differentiation, and inhibits bone formation [50] . In osteoblasts, miR-34c targets multiple components of the Notch signaling pathway, including NOTCH1, NOTCH2 and JAG1 in a direct manner, and influences osteoclast differentiation in a non-cell-autonomous fashion [51] .
Accumulating evidence suggests that the expression of β-catenin is, in part, regulated by specific microRNAs (miRNAs). miR-214 was demonstrated to directly interact with the 3'-untranslated region of the β-catenin gene CTNNB1, and suppressed Wnt/β-catenin signaling through the inhibition of β-catenin [52] . miR-139-5p exerts its role in BMSC osteogenesis most probably through direct targeting CTNNB1 and frizzled 4 (FZD4) [53] . MiR-376c inhibits osteoblastogenesis by targeting WNT3 and ARF-GEF-1 -facilitated augmentation of β-catenin transactivation [54] . MiR-26a is majorly target on GSK3β to activate WNT signaling for promoting osteogenic differentiation of BMSCs [55] . In this study, we demonstrated that miR-16-2* can suppress osteoblast differentiation of hBMSCs through regulating WNT5A-mediated WNT pathway. MiR-16-2* can be directly targeted to the 3-terminal non-coding region of WNT5A and regulate its expression. Downregulation of WNT5A can simulate the inhibitory effect of miR-16-2* on osteoblast differentiation of hBMSCs. The expression levels of CTNNB1 and LRP5/6 were significantly reduced in the overexpression of miR-16-2* or interference with endogenous WNT5A. The blocking of WNT signal with DKK1 can not only obviously inhibit osteogenesis differentiation, but also partly weaken the promotion of osteogenesis differentiation by suppression the expression of endogenous miR-16-2*. We speculate that WNT5A regulates osteogenesis and may function through both canonical and non-canonical WNT pathways.
Conclusion
The regulation of osteoblast differentiation is very important for the intervention of osteoporosis. The insafety of gene compilation and the complexity of gene regulation make it difficult to be an effective target for osteoporosis prevention. MiRNA has an advantage in the prevention and treatment of osteoporosis due to its unconformity characteristics, easy synthesis in vitro and multi-target characteristics of regulation. For the first time, we found
